arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Global Pharmaceutical and Biotechnology Conference 2018

Embracing Disruption for a New Era in Health

London |  - 
Speakers include:
Hal Barron

Hal Barron

GlaxoSmithKline

Christophe Weber

Christophe Weber

Takeda Pharmaceutical Company

Joanne  Waldstreicher

Joanne Waldstreicher

Johnson & Johnson

Overview

The global life sciences industry is facing a level of disruption unprecedented in its long history. Once considered the holy grail of medicine, a new generation of gene-based therapies is dawning at last, holding out the promise of a paradigm shift from treatment to cure, but also challenging our healthcare systems’ ability to afford the new age of biology.  China, meanwhile, is rising as a force to be reckoned with, both in terms of its potential for drug development, as well as in its ready embrace of digital technologies to transform R&D, disease management and services.

The Financial Times Annual FT Global Pharmaceutical and Biotechnology Conference, now in its 36th successful year brings together the industry’s top executives and visionaries to explore the latest trends set to reshape the industry far into the future - from new R&D models and digital therapeutics to patient centricity and population health management.

fallback
fallback Add to my Calendar 11/05/2018 12:00:0011/06/2018 18:00:00trueFT Global Pharmaceutical and Biotechnology Conference 2018The global life sciences industry is facing a level of disruption unprecedented in its long history. Once considered the holy grail of medicine, a new generation of gene-based therapies is dawning at last, holding out the promise of a paradigm shift from treatment to cure, but also challenging our healthcare systems’ ability to afford the new age of biology.  China, meanwhile, is rising as a force to be reckoned with, both in terms of its potential for drug development, as well as in its ready embrace of digital technologies to transform R&D, disease management and services.The Financial Times Annual FT Global Pharmaceutical and Biotechnology Conference, now in its 36th successful year brings together the industry’s top executives and visionaries to explore the latest trends set to reshape the industry far into the future - from new R&D models and digital therapeutics to patient centricity and population health management.FT-Global-Pharmaceutical-and-Biotechnology-Conference-20180fd3ab4eda1b8c59fc5147f57691a815MM/DD/YYYY

Brochure download

Brochure download

Download now

Event Brochure

To download the event brochure please fill in the form below. All fields are required

Please complete all the highlighted fields

Form submission failed. Please retry.

For more information about how we use your data please refer to our privacy and cookie policies.

Invites and offers from the FT

Receive exclusive personalised events invitations, carefully-curated offers, future speaking engagements and promotions from Financial Times Live

Thank you for submitting your details. Please download the event brochure.

2018 Photos

View photos from the 2018 Summit here.

FT Pharma Bio 2018-8920

More

Sneak Peek video 2018

ETNO Preview

More

2017 Photos

View photos from the 2017 Summit here.

37698300154_663ef018d4_k

fallback

2017 Testimonials

“The FT Pharma and Biotech Conference is the leading event for getting a glimpse of the future of healthcare.” Philipp Gutzwiller, Global Head of Healthcare, Lloyds Bank

“FT Pharma is an insightful meet for learning and networking” Seppa Orsila, Executive Chairman, Modulight

“The FT conference offers a perfect balance of hard-hitting topics that are relevant to today's pharma/biotech industries” Faraz Kermanz, Comms Manager, EFPIA

“Great meeting to hear about the latest thinking from senior leaders in life sciences industry” Matt Cooper,  Business Development Director, Nihr Clinical Research Network

“FT conferences really provide high value information and world class speakers” Viky Maniala, Managing Director, Transped

fallback

Speakers list (57)

Hal Barron

Hal Barron

Chief Scientific Officer and President, R&D
GlaxoSmithKline

Hal joined GSK as Chief Scientific Officer and President, R&D on 1 January 2018. He is a member of the Board and the Corporate Executive Team.

His previous role was President, R&D at Calico (California Life Company). Prior to this, Hal was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer.

Hal was previously a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc. 

He is Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco. He is Non-Executive Board Director of GRAIL, Inc, an early cancer detection healthcare company.

Hal holds a Bachelor of Science degree in Physics from Washington University in St. Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.

He has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.

Christophe Weber

Christophe Weber

President and Chief Executive Officer
Takeda Pharmaceutical Company

Christophe Weber is President and Chief Executive Officer of Takeda Pharmaceutical Company Limited. He joined Takeda in April 2014 as Chief Operating Officer, was named President and Representative Director in June 2014, and was subsequently appointed Chief Executive Officer in April 2015. Mr Weber has introduced key transformation changes within the global organisation which focus on the underlying principles of patient and customer-centricity, accountability and being as agile as possible for a global company. Mr Weber has held leadership roles across many different businesses and geographies. Prior to joining Takeda, Mr Weber held positions of increasing responsibility at GlaxoSmithKline (GSK) including President & General Manager at GSK Vaccines, CEO of GSK Biologicals SA in Belgium, and member of the GSK global Corporate Executive Team. From 2008 to 2010, Mr Weber served as Asia Pacific SVP and Regional Director at GSK Asia Pacific in Singapore. Mr Weber holds a doctorate degree in Pharmacy & Pharmacokinetics from the University of Lyon, France. There, he also earned Master’s degrees in Pharmaceutical Marketing and in Accounting and Finance, as well as a Bachelor’s degree in Statistics.

Joanne  Waldstreicher

Joanne Waldstreicher

Chief Medical Officer
Johnson & Johnson

Joanne Waldstreicher, M.D., is Chief Medical Officer, Johnson & Johnson. In this role, she has oversight across pharmaceuticals, devices and consumer products for safety, epidemiology, clinical and regulatory operations transformation, collaborations on ethical science, and technology and R& D policies, including those related to trial transparency and compassionate access. She Chairs the R&D development pipeline review committee for Janssen, the pharmaceuticals group of Johnson & Johnson, and supports Device and Consumer Development committees. Dr Waldstreicher is also a Faculty Affiliate of the Division of Medical Ethics, Department of Population Health, New York University School of Medicine. Among her prior roles, she was responsible for late-stage development in neuroscience, cardiovascular disease and metabolism at Janssen. Before joining Johnson & Johnson in 2002, Dr Waldstreicher headed Endocrinology and Metabolism clinical research at Merck Research Laboratories, overseeing development programs in atherosclerosis, obesity, diabetes, urology and dermatology. She was honoured with the Key Innovator Award, among other distinctions. Dr Waldstreicher, received both the Jonas Salk and Belle Zeller scholarships from the City University of New York, and graduated Summa Cum Laude from Brooklyn College. She graduated Cum Laude from Harvard Medical School, completed her internship and residency at Beth Israel Hospital, and her endocrinology fellowship at Massachusetts General Hospital. She has received numerous awards and scholarships, and is an active scientific author. In 2016, the National Association of Female Executives named her Healthcare Champion of the Year.

Rajni Aneja

Rajni Aneja

Connection Science Fellow
MIT Connection Science

Rajni Aneja is an MIT Connection Science Fellow, health care strategist, public speaker, transformative change agent with expertise in population health management and digital health. She serves as an advisor to variety of health and wellness organisations. Dr Aneja encompasses various vantage points as a clinician, executive, advisor, entrepreneur, speaker and technology advocate serving in senior leadership roles to include Chief Medical Officer for WebMD health, EVP of Joslin and strategic executive, transformation leader at Humana and most recently contributed to the builing of a digital consumer strategy at Novartis. Dr Aneja is spreading the vision for strategy and innovation across different spectrums of health care Dr. Aneja received her MD from Research Medical Center in Kansas City and MBA from University of Massachusetts.

Lisa  Anson

Lisa Anson

CEO
Redx Pharma

Lisa Anson is Chief Executive Officer of Redx Pharma plc, appointed in June 2018. She held the post of President of AstraZeneca UK since 2012 and has significant leadership experience in pharmaceuticals. Over a 20 year career at AstraZeneca plc, Ms Anson held a number of senior management roles in both the US and the UK including Global Vice President, Oncology and as Vice President of emerging brands where she worked closely with the Research and Development teams. She joined Zeneca Pharmaceuticals (USA) in 1998 as a business development manager. Prior to this she worked for Salick Health Care (now Aptium), a California based cancer disease management company. Her first position upon graduating from university was with KPMG in London as a management consultant

Ms Anson is President of the Association of the British Pharmaceutical Industry (ABPI) a position from which she will step down in 2018. She has been a Board member of the ABPI since 2012 where she has chaired a number of UK industry committees and worked closely with Government.

Ms Anson holds an MBA (awarded with distinction) from INSEAD, France and a First Class honours degree in Natural Sciences from Cambridge University in the UK. 

Andrew Badrot

Andrew Badrot

CEO
C2 Pharma

Andrew Badrot is the founder and CEO of C2 PHARMA, a Luxembourg-based pharmaceutical group established in 2014 following an acquisition of a product portfolio of active pharmaceutical ingredients (APIs) from a leading German Pharmaceutical group. Today, C2 PHARMA manufactures and distributes APls and complex chemical compounds obtained from natural and synthetic origins.

Andrew has over 20 years of business practice in technology-driven industries affected by commoditization. Over the past 10 years, he has focused his work on APIs and has built a network of business partners spanning the globe, from India to Brazil.

Andrew holds a MS degree in Financial Engineering from Stanford University, California, USA, and an Engineering degree in Nuclear Physics from Institut Polytechnique, France.

Professor Sir John Bell

Professor Sir John Bell

Regius Professor of Medicine, Government Advisor on UK Life Sciences Strategy
Oxford University

Professor Sir John Bell is Regius Professor of Medicine at Oxford University and the former President of the Academy of Medical Science. He has been extensively involved in the development of research programmes in genetics and genomics and in the development of clinical research programmes across the UK. Professor Bell was the Founder of the Wellcome Trust Centre for Human Genetics and has led the significant expansion in biomedical research activities in the Clinical School in Oxford since 1992. He is a non-executive director of Roche AG (since 2001) and of Genentech (since 2009). He is also a member of the Bill and Melinda Gates Foundation Scientific Advisory Committee and a Board Member of the UK Clinical Research Collaboration and UK Biobank. Professor Bell is currently the Life Sciences Champion to the UK Prime Minister advising on Life Sciences Strategy.  

Christopher Boerner

Christopher Boerner

Executive Vice President and Chief Commercial Officer
Bristol-Myers Squibb

Christopher Boerner is currently Executive Vice President and Chief Commercial Officer at Bristol-Myers Squibb (BMS). Prior to this he was Head of International Markets and accountable for commercial activities in all ex-US markets. This followed a position as the company's  Head of the US Commercial business. He joined BMS in February 2015. Prior to joining BMS, Dr Boerner served as the Executive Vice President of Commercial for Seattle Genetics, Inc., where he led all commercial activities for the company. Previously, he was its Senior Vice President of Commercial and its Vice President of Marketing. Before joining Seattle Genetics, he was with Dendreon Corporation, where he led the marketing team. From 2002 to 2010, he was with Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including Director of Marketing on Avastin, Director of Avastin franchise strategy and Associate Director of Oncology Market Development. Prior to Genentech, he was with McKinsey & Company, a global strategic management consulting firm, where he served global pharmaceutical and biotechnology clients.Dr Boerner received his PhD and MA in Business Administration from the Haas School of Business at the University of California, Berkeley, and holds an A.B. in Economics and History from Washington.

Katrine Bosley

Katrine Bosley

CEO
Editas Medicine

Katrine Bosley is the Chief Executive Officer of Editas Medicine. Prior to joining Editas, Ms Bosley was an Entrepreneur-in-Residence at The Broad Institute, a biomedical and genomic research center, and before that, she was the CEO of Avila Therapeutics (acquired by Celgene). She was also Vice President, Business Development at Adnexus Therapeutics and then Vice President, Strategic Operations after Adnexus’ acquisition by Bristol-Myers Squibb. Earlier, Ms Bosley held several positions at Biogen in Business Development, Commercial Operations, and Portfolio Strategy and was part of the healthcare team at the venture firm Highland Capital Partners.

 

In addition to her role at Editas, Ms Bosley currently serves as Chairman of the Board of Genocea Biosciences (NASDAQ: GNCA) and is a member of the Board of Directors of Galapagos NV (EURONEXT and NASDAQ: GLPG), of BIO – the Biotechnology Innovation Organization, and of Massachusetts Eye and Ear.

 

Ms Bosley is a graduate of Cornell University.

 

Billy Boyle

Billy Boyle

Co-Founder and CEO
Owlstone Medical

Billy Boyle co-founded Owlstone Inc. in Cambridge in 2004. The company develops, manufactures and supplies advanced chemical detection solutions across a wide range of markets and applications and has raised $28M in investment and won over $25M in defence contracts. Mr Boyle initially worked with silicon foundries in the design and fabrication of the core microchip technology and is co-inventor on 19 patents. He then assumed a commercial role with P&L responsibility for the Scientific Instruments and Industrial business units; responsible for sales of FAIMS products and contracts with over 150 clients globally, including Agilent, Thermo, Roche Diagnostics, Samsung, GSK, 4D Pharma, Mayo Clinic and the NHS. Mr Boyle started to focus on the medical applications of FAIMS technology after his wife, was diagnosed and later died of colon cancer as a result of a late diagnosis. He headed up the newly formed Medical business unit, with the ongoing clinical and commercial success, and investment, he spun out Owlstone Medical Ltd in March 2016. Mr Boyle, an engineering graduate from Cambridge University, is a judge for the Cancer Research UK (CRUK) Pioneer award and a Trustee of the Linacre Institute.  

Sohini Chowdhury

Sohini Chowdhury

Deputy CEO
The Michael J Fox Foundation for Parkinson's Research

Sohini Chowdhury joined The Michael J Fox Foundation in 2005. As Deputy CEO, she oversees the Research Partnerships team and works closely with the Foundation's executive leadership and Board of Directors in building the organization’s capacity as an unprecedented stakeholder in drug development — a nimble, resourceful, patient-focused problem-solver whose efforts are demonstrably accelerating progress toward treatment breakthroughs and a cure. Ms Chowdhury  was elevated to the role of Deputy CEO in 2017. In her previous capacity as SVP, Research Partnerships at the Foundation, she established and led the formal industry strategy, building ongoing relationships with pharmaceutical firms and biotechs as research partners and as sponsors of the Foundation’s scientific and educational programs. She has led development of programs critical to increasing patient engagement in Parkinson’s research including the Fox Trial Finder smart-match tool and Fox Insight.  Ms Chowdhury also is responsible for administrative and operational oversight of the MJFF-sponsored landmark clinical study PPMI, or the Parkinson’s Progression Markers Initiative, launched by MJFF in 2010 to identify and validate Parkinson’s biomarkers. Prior to joining MJFF, she worked at the World Economic Forum for five years. As the Senior Community Manager of the Forum's Technology Pioneers program, she was responsible for annually selecting and integrating innovative biotech, energy and IT technology companies into Forum activities.  She also worked directly for the Forum's CEO, acting as his liaison with key Forum stakeholders and overseeing several in-house projects.  Ms Chowdhury graduated with an MA from Georgetown University, and holds a BA in International Studies from Vassar College.

Matt Cooper

Matt Cooper

Business Development & Marketing Director / Research Delivery Director
National Institute for Health Research Clinical Research Network Coordinating Centre

The NIHR Clinical Research Network is the research delivery arm of the NHS. It invests £300m each year into an infrastructure of clinical research professionals, to support recruitment into clinical research studies (over 725,000 participants in 2017/18).

A Director at the Network since 2014, Dr Cooper brings a wealth of experience to the post, having been part of the Network structure for a decade. Recently, Dr Cooper has also taken on the additional responsibility of Research Delivery Director.

In previous roles he was a member of the leadership team of the National Cancer Research Network and worked in the Clinical Research Group of AstraZeneca.

Pamela Cyrus

Pamela Cyrus

Vice President and Head of Global Medical Governance
Bayer Pharmaceuticals

Pamela Cyrus has served as Vice President and Head of Global Medical Governance since July 2014. This role has oversight responsibility to protect the interests of patients in accordance with all relevant legislation and guidelines including EU, FDA and country directives, Medicines Law, the Pharmaceutical Industry Code of Practice, and company standard operating procedures. This role reports to the Bayer Chief Medical Officer. Prior to this, from 2009 to 2014, she was the Vice President and Head of US Medical Affairs at Bayer Pharmaceuticals. Ms Cyrus has more than 20 years’ experience in the pharmaceutical industry, having led and managed large teams across different therapeutics areas (neurology, pulmonary, biologics, oncology, anti-infectives, cardiovascular, metabolics, diagnostic imaging, and women’s healthcare). She has had responsibilities in both clinical development and medical affairs. Prior to joining the pharmaceuticals industry, Dr Cyrus served as a physician. Having received her MD from the Marshall University School of Medicine, Huntington, West Virginia and completed her internship in internal medicine at Marshall University School of Medicine. She then completed her neurology residency and geriatric neurology fellowship at Boston University School and the Boston Veterans Administration Hospital. Dr Cyrus earned a Bachelor’s degree in chemistry from Marshall University.

Peter Donnelly

Peter Donnelly

Founder and CEO
Genomics plc, Professor of Statistical Science in the Wellcome Centre for Human Genetics, University of Oxford

Professor Peter Donnelly FRS FMedSci is Founder and CEO of Genomics plc and latterly Director of the Wellcome Centre for Human Genetics at the University of Oxford, where he is also Professor of Statistical Science.

Peter has been one of the global leaders in the “Genetic Revolution”, the explosion in our knowledge of the genetic basis of human diseases, and the increasing use of genome sequencing in clinical medicine. Genomics plc has developed the largest database of its kind combining genetic data on individuals with molecular, cellular, biomarker, and disease measurements and uses its sophisticated statistical and machine learning algorithms to extract novel insights from this platform to transform drug discovery and development.

Mark Douglas

Mark Douglas

Vice President, Strategic Business Development
FUJIFILM Diosynth Biotechnologies.

Mark Douglas leads global strategic business development activities across the FUJIFILM Diosynth Biotechnologies group. He has more than 20 years' experience in the pharmaceuticals, contract development and manufacturing sectors in technical, sales and marketing, IP and business development roles. Before joining the pharmaceutical industry, Mr Douglas held a staff scientist position at EMBL, Heidelberg, Germany. He is a chemist by training and completed his degree and PhD at the University of Liverpool, UK.  

Yves Dubaquie

Yves Dubaquie

Head of Global Business Development
MilliporeSigma

Yves Dubaquie is the Head of Global Business Development at MilliporeSigma, the Life Science business of Merck KGaA, Darmstadt, Germany. In this role Yves is responsible for setting the inorganic growth strategy for the company’s Research Solutions, Process Solutions and Applied Solutions business units. This includes all aspects of opportunity sourcing, deal execution and integration (e.g. acquisitions, strategic alliances, joint ventures and divestitures). 

Previously, Yves was Managing Director, Business & Corporate Development at GE Healthcare Life Sciences, a global $4B GE Healthcare division, located in Amersham, UK.

Prior to GE, Yves held several global business development and licensing roles for pharmaceutical and biotech companies such as Novartis, Ironwood Pharmaceuticals, and Bristol-Myers Squibb. In these roles he successfully executed transactions in drug development and commercialization, molecular diagnostics, and medical imaging technologies. 

Yves holds a Ph.D. in Biochemistry from the University of Basel, Switzerland. After conducting postdoctoral research at Genentech he led pre-clinical and early stage clinical drug development teams at Bristol-Myers Squibb before transitioning into business development.

Chris Edson

Chris Edson

CEO
OurPath

Chris Edson is the CEO of OurPath – a digital behavioural change programme for people at risk for developing type 2 diabetes. In 2018, he was selected as one of ‘Forbes 30 under 30’ in healthcare. Mr Edson previously worked as a healthcare consultant, advising pharmaceutical, private health, and public sector organisations in the UK healthcare system. His repeated exposure to the poor patient outcomes and high costs associated with diabetes provided the stimulus for OurPath, which he’s been building for the last three years. Mr Edson graduated from Oxford University in Engineering and holds an MEng in Quantum Computing.

Thomas Eichholtz

Thomas Eichholtz

Executive Director of External R&D
Mundipharma Research

Thomas Eicholtz joined Mundipharma Research as Executive Director of External R&D in February 2018, and leads the efforts to build an innovative, externally sourced pipeline with neurology and inflammation projects for pain and adjacent diseases.

 

Prior to joining Mundipharma Dr Eicholtz was Head of Discovery, and then Head of R&D at Almirall in Spain, he has also worked at AstraZeneca, Pfizer and GSK in the UK, France and Sweden in a variety of different roles focussed on translational sciences.

 

Dr Eicholtz has a degree in Biology from the University of Utrecht and a PhD in Cellular Biochemistry obtained at the Netherlands Cancer Institute in Amsterdam.

Dr Hans-Georg Eichler

Dr Hans-Georg Eichler

Senior Medical Officer
European Medicines Agency (EMA)

Hans-Georg Eichler, MD, MSc, is the Senior Medical Officer at the European Medicines Agency (EMA) in the United Kingdom, where he is responsible for coordinating activities between the Agency’s scientific committees and giving advice on scientific and public health issues. Prior to joining the European Medicines Agency, Dr Eichler was at the Medical University of Vienna in Austria for 15 years. He was Vice-Rector for Research and International Relations from 2003, and Professor and Chair of the Department of Clinical Pharmacology from 1992. His other previous positions include president of the Vienna School of Clinical Research and co-chair of the Committee on Reimbursement of Drugs of the Austrian Social Security Association. His industry experience includes time spent at Ciba-Geigy Research Labs, UK, and Outcomes Research at Merck & Co, in New Jersey. In 2011, Dr Eichler was the Robert E. Wilhelm fellow at the Massachusetts Institute of Technology’s Center for International Studies, participating in a joint research project under the MIT’s NEWDIGS initiative.

Dr Eichler graduated with an MD from Vienna University Medical School and a Master of Science degree in Toxicology from the University of Surrey in Guildford, UK. He trained in internal medicine and clinical pharmacology at the Vienna University Hospital as well as at Stanford University.

Richard Francis

Richard Francis

CEO
Sandoz

Richard Francis has been CEO of Sandoz since 2014. He is a member of the Executive Committee of Novartis. Mr Francis has over 20 years of experience in the pharmaceutical industry through various country and global commercial leadership roles. He joined Novartis from Biogen Idec, where he was most recently Senior Vice President of the company’s United States commercial organisation. From 1998 to 2001, he was at Sanofi in the United Kingdom, and held various marketing roles across the company’s urology, analgesics and cardiovascular products. He also held sales and marketing positions at Lorex Synthélabo and Wyeth. Mr Francis is a member of the Board of Directors of Mettler-Toledo International Inc. He received a Bachelor of Arts in Economics from Manchester Metropolitan University in the UK.

Ken Gabriel

Ken Gabriel

President and CEO
Draper

Kaigham J. (Ken) Gabriel is currently President and CEO of Draper. Most recently he co-founded Google’s Advanced Technology and Projects (ATAP) group. Prior to this, he was Deputy and Acting Director of the Defense Advanced Research Projects Agency (DARPA) in the U.S. Department of Defense, managing a $3bn annual program portfolio of the Departments most cutting-edge projects. During his tenure, DARPA advanced capabilities in hypersonics, offensive and defensive cyber, and big data analytics for intelligence & national security. Mr Gabriel is regarded as the ‘godfather’ of MEMs – miniaturized and integrated mechanical & electrical technology, which helps phones orient themselves, car air bags to know when to fire, biomedical devices save lives, and create entirely new capabilities with smaller size, weight and power. His work is recognised widely throughout many industries, and he was honored as a Technology Pioneer by the World Economic Forum at Davos. Mr Gabriel is the leading expert on the concept of disciplined innovation, and the ways in which businesses can reliably and consistently create breakthrough innovations.

Julie Gerberding

Julie Gerberding

Executive Vice President, Communications, Global Policy, and Population Health & Chief Patient Officer
MSD

Dr Julie Gerberding is responsible for Merck’s commercial portfolio of vaccines, planning for the introduction of vaccines from the company's pipeline, and accelerating access to vaccines around the world. She also co-chairs the Board of Sanofi Pasteur MSD vaccines (a joint venture in Europe). Dr Gerberding served as Director, US. Centers for Disease Control and Prevention (2002-2009) where she led numerous emergency responses to public health crises, including anthrax bioterrorism, SARS, Ebola, and natural disasters. Dr Gerberding is a passionate advocate for sustainable global health solutions and serves on the Boards of Directors of Project HOPE, Accordia Global Health Foundation and the MSD Wellcome Trust Hilleman Laboratories (India).

Mike Gladstone

Mike Gladstone

Global President, Internal Medicine, Pfizer Innovative Health
Pfizer

Mike Gladstone is the Global President of Internal Medicine at Pfizer Inc., one of the world’s premier innovative biopharmaceutical companies.  He is responsible for a $9 billion global portfolio of medicines spanning cardiovascular metabolic and pain therapeutic areas.  He oversees approximately 8,000 colleagues, including Pfizer’s Country Managers and Medical Directors who represent the company to external stakeholders globally.  Mr Gladstone has over 25 years of experience in the pharmaceutical industry and has held a number of senior global positions across Pfizer.

Prior to this position, Mr Gladstone was the North America Regional President for Internal Medicine.  In addition, he was appointed as the US Country Manager for Pfizer.  Before this, he was the Chief Marketing Officer for the US Primary Care Business Unit. 

Previously, Mr Gladstone spent three years living in Sweden and three years in Italy where he held multiple positions including serving as the European Specialty Care Asset Team Leader for Inflammation and all Specialty Care brands for 16 countries in Europe and as the Managing Director for the Nordic countries.

Earlier in his career, Mr Gladstone advanced through various positions in Sales, Marketing, Healthcare Systems, National Accounts and General Management in the US and eventually became Vice President for Gastroenterology and Metabolic Diseases.

 Mr Gladstone serves on the board of the U.S. Healthcare Leadership Council and he retains a seat on the Executive Committee.  He is also on the board of the Partnership for America’s Health Care Future and previously was on the board of the National Pharmaceutical Council.

Jane  Griffiths.

Jane Griffiths.

Global Head
Actelion

With over 30 years of experience in the healthcare industry, Jane Griffiths is currently the Global Head at Actelion Pharmaceuticals Ltd. She is also Chair of the Johnson & Johnson Corporate Citizenship Trust in EMEA and Sponsor of the Janssen Global Pharmaceuticals Sustainability Council. Prior to stepping into her role at Actelion in June 2017, Dr Griffiths was Company Group Chairman at Janssen EMEA (the pharmaceutical arm of Johnson & Johnson) for over six years, responsible for the entire business across the region. As the company’s first female to have held that role, she is passionate about encouraging more female talent to pursue leadership roles. She is a Sponsor of the Johnson & Johnson Women’s Leadership Initiative. Outside of Johnson & Johnson, Dr Griffiths is also a member of the EFPIA Board, past Chairwoman of the EFPIA Executive Committee, and past Chairwoman of the PhRMA Europe Committee. Dr Griffiths is a passionate advocate for women in business and STEM education. To support this, she sits on the Advisory Board for ‘Your Life’ a program committed to encourage young people to study STEM subjects and pursue a career in Science. Since completing her PhD in Plant Biochemistry at the University College of Wales, Aberystwyth, UK, in 1985, Dr Griffiths has held various roles within Johnson & Johnson, starting as a sales representative. She has gained in-depth knowledge of oncology, haematology and psychiatry, and significant experience in HIV and HCV. Her previous roles include international and affiliate marketing, sales management, sales, product management, and clinical research.

Jay Hamilton

Jay Hamilton

Associate Director
Health Innovation Manchester

Jay Hamilton, Associate Director of Health and Implementation, has led on both Patient Safety and Medicines Optimisation work streams for two years at Health Innovation Manchester (HInM). In addition, her programme of work extends further to support the Association of British Pharmaceuticals Industry (ABPI)  HInM working group. Prior to joining Health Innovation Manchester, Ms Hamilton ran her own consultancy business which - underpinned by a long and established career in the pharmaceutical industry – built and strengthened joint-working between the pharmaceutical and NHS sectors.

Deborah Harland

Deborah Harland

Partner
SR One

Deborah Harland is a Partner at SR One, the corporate venture capital arm of GlaxoSmithKline. She joined in 2005 to establish the firm’s European investment office.  She leads the investment team in Europe and represents SR One’s interest on the Board of Directors of several innovative biotech companies including Asceneuron, Mission Therapeutics, Bicycle Therapeutics, f-star, and VHsquared.   Prior to SR One, Debbie gained extensive operational, drug development and licensing experience through numerous roles held in clinical development, medical affairs and business development over a 17 year period at Merrell Dow, SmithKline Beecham and GSK.  Since October 2015, Debbie has also been an independent director on the board of Cancer Research Technology, the commercialisation arm of Cancer Research UK.

Christian Hogg.

Christian Hogg.

CEO
Chi-Med

Mr Hogg joined Chi-Med in 2000, as its first employee, and has since led all aspects of the creation, implementation and management of the company’s strategy, business and listings.  This includes the establishment of the company’s Innovation Platform, which now comprises eight clinical drug candidates, primarily in oncology, in over 30 clinical studies around the world and a scientific team of over 330 people based in Shanghai.   Furthermore, the acquisition and operational integration of assets that led to the formation of the company’s Commercial Platform which manufactures and markets over 200 drugs through a team of over 3,300 marketing personnel covering over 300 cities and towns in China. Prior to joining Chi-Med, Mr Hogg spent ten years with P&G starting in the US in Finance and then Brand Management in the Laundry and Cleaning Products Division. Mr Hogg then moved to China to manage P&G’s detergent business followed by a move to Brussels to run P&G’s global bleach business. Mr Hogg received a Bachelor’s degree in Civil Engineering from the University of Edinburgh and an MBA from the University of Tennessee.

Chris Hollowood

Chris Hollowood

Chief Investment Officer
Syncona

Chris Hollowood is the Chief Investment Officer and a Managing Partner of Syncona Investment Management Ltd. Previously, he was a partner of Apposite Capital LLP, a venture and growth capital healthcare investment company. During his time at Apposite, he was involved in a number of investments, which included Ambit Biosciences, Convergence Pharmaceuticals, Birdrock and the acquisition of a portfolio of nine US healthcare companies which included Zonare Medical Systems and Ulthera. Prior to Apposite, Mr Hollowood had roles with Bioscience Managers Ltd, Neptune Investment Management Ltd and in the pharmaceutical industry. Mr Hollowood holds a degree in Natural Sciences and a PhD in Organic Chemistry, both from the University of Cambridge

Bruno Holthof

Bruno Holthof

CEO
Oxford University Hospitals Foundation Trust

Bruno Holthof is the Chief Executive Officer (CEO) of Oxford University Hospitals Foundation Trust (OUHFT). OUHFT employs 12,000 staff across four hospital sites and 44 other locations. Before OUHFT, he was CEO of the Antwerp Hospital Network (ZNA) from January 2004 until September 2015. During this period, he transformed ZNA into the most profitable hospital group in Belgium. Prior to becoming a CEO, he was a partner at McKinsey & Company. During this period, he served a wide range of healthcare clients in Europe and the United States and gained significant expertise in the areas of strategy, organisation and operations. Dr Holthof is a member of the Board of Armonea, a European private care home provider. He holds an MBA from the Harvard Business School and an MD/PhD from the University of Leuven.

Leslie Krumholz

Leslie Krumholz

CEO
Hugo Health

Leslie Krumholz is a social entrepreneur dedicated to improving lives through technology. As the CEO of Hugo Health, a transformative new technology radically changing how information is collected and shared for clinical research. Ms Krumholz is working with industry leaders to redefine what it means to engage people as partners in research, while powering faster, more efficient and more affordable innovation. Of the three inaugural demonstration projects, for the FDA’s National Evaluation System for Health Technology (NEST), two included Hugo Health. Prior to co-founding Hugo Health, Ms Krumholz was CEO of GoodStreets, one of Connecticut’s first Benefit Corporations and a “Connecticut Tech Company to Watch”. She is a recipient of the reSET Social Enterprise Award and a Connecticut Tech Council Women of Innovation Honoree. Ms Krumholz has a BA from the University of Massachusetts/Amherst and a JD from the University of California, Hastings College of Law.

Niels Lund

Niels Lund

Vice President, Health Advocacy
Novo Nordisk

Niels Lund is Vice President for Health Advocacy in Novo Nordisk, a global healthcare company with more than 90 years of innovation and leadership in diabetes care.

Mr Lund is responsible for managing Changing Diabetes flagship programmes (including Cities Changing Diabetes), and the Access to Insulin Commitment (including Changing Diabetes in Children and Partnering for Change with the International Committee for the Red Cross). Furthermore, his responsibilities include partnerships with patient organisations and patient advocates globally.

Mr Lund acts as co-Chair of the Health and Healthcare Strategy Officers’ Council in the World Economic Forum (WEF) and is a contributor to WEF's Agenda blog platform. 

Mr Lund joined Novo Nordisk in 2007 as a health economist and worked in various functions before being appointed Vice President for Public Affairs in 2012. Before joining Novo Nordisk, Mr Lund worked in international development with assignments for UNICEF in India and the World Bank in Washington DC.

Paul Major

Paul Major

Portfolio Manager
BB Healthcare Trust

Paul is a portfolio manager for the BB Healthcare Trust, a UK Trust investing in disruptive innovation in healthcare through a concentrated and unconstrained long-only portfolio. Paul has more than 20 years’ experience covering the healthcare sector, and has worked at Bellevue Asset Management since 2016. He was previously a Partner at Redburn, a leading Independent sell-side broking firm, where he covered the healthcare sector with a major focus on bespoke work, including portfolio construction for several institutions. He has previously worked as an analyst and corporate financier at UBS/SBC Warburg and studied Biochemistry.

Mark Mallon

Mark Mallon

Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs
AstraZeneca

Mark Mallon was appointed Executive Vice-President (EVP), Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs in August 2016, leading AstraZeneca’s global marketing and commercial portfolio strategy as well as the medical and corporate affairs functions. These functions integrate corporate, therapy area and product strategies to bridge scientific development and commercial excellence in the core areas of cardiovascular and respiratory diseases. Prior to this, Mr Mallon was Executive Vice President for the International region with responsibility for the growth and performance of AstraZeneca’s commercial businesses in various parts of the world, including Asia Pacific, Russia, Latin America, the Middle East and Africa. Since joining AstraZeneca in 1994, Mr Mallon has held many senior sales and marketing roles, including Regional Vice-President for Asia Pacific, President of AstraZeneca’s Chinese and Italian subsidiaries, Chief Operating Officer of AstraZeneca’s Japanese subsidiary and Vice-President of AstraZeneca’s US gastrointestinal and respiratory businesses. Mr Mallon began his career in the pharmaceutical industry in management consulting. He holds a degree in Chemical Engineering from the University of Pennsylvania and an MBA in Marketing and Finance from the Wharton School of Business.

Richard  Mason

Richard Mason

Co-Founder
The Foundation Institute for 21st Century Medicine (C21Med)

Richard Mason, MD, is Co-Founder of The Foundation Institute for 21st Century Medicine (‘C21Med’), an initiative of venture capital firm Medicxi

Dr. Mason served as Head of Johnson & Johnson’s London Innovation Centre from October 2015 to April 2018, where he was responsible for Johnson & Johnson Innovation within the EMEA region. In this role, Dr. Mason led a team of transaction and scientific innovation experts to identify and develop a diverse portfolio of early-stage partnerships and investments across all three sectors of J&J.
 
Prior to joining J&J, Dr Mason was CEO of a venture-backed biotechnology startup, XO1 Ltd. until the company was acquired by Janssen Pharmaceuticals (a subsidiary of J&J) in March 2015. Prior to that, he was Head of Strategy and Business Development and member of Executive Leadership Team at specialty pharmaceutical and medical device company BTG Plc (LON: BTG), where he led its transformation into a leading interventional medicine company through multiple acquisitions including Ekos Corporation, Biocompatibles Plc, and MDS Nordion’s Therasphere business. Dr.Mason also served as an Executive-in-Residence for Advent Venture Partners where he served as a turnaround CEO for several portfolio companies. Prior to that he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT) and member of the CAT Executive Leadership Team.
 
Dr. Mason trained in Medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree in immunology from University College, London and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management.

Bernard Massie

Bernard Massie

Director General (Acting),Human Health Therapeutics Research Centre
National Research Council (NRC), Canada

In December 2015, Dr Bernard Massie was appointed Director General (Acting) of the Human Health Therapeutics Research Centre at the NRC. Profoundly inspired by the biotechnology pioneers who developed recombinant DNA in 1973, and by its application in 1978 to produce human insulin, Dr Bernard Massie joined the NRC in 1985 with a conviction that molecular biology holds the power to unlock the mysteries of human health. He initially focused on delivering DNA inside cells to replace mutated genes with therapeutic genes, becoming one of the first researchers in Canada to tackle gene therapy. Sensing the enormous potential of biologics to treat cancer and chronic diseases, he applied his knowledge of viral vectors to biologics production. He has dedicated 30 years to developing bioprocesses needed to produce these revolutionary, targeted medicines, first as a research associate and progressing to roles such as Group Leader, R&D Director, and Leader of the Biologics and Biomanufacturing Program. Dr Massie earned his BSc and MSc in Biology from Université de Montréal, where he also completed his PhD. in Microbiology. He has published over 140 peer-reviewed papers and has 12 issued patents.

Philip  Maurer

Philip Maurer

Pharmaceutical and Health Care Engineering Lead
Google Cloud, UK

Philip Maurer leads the Healthcare and Government technical teams within Google Cloud UK and Ireland.

He has been with Google Cloud for almost four years and has a background in Genomics, Microservices and Machine Learning.

William Mayo

William Mayo

Chief Information Officer
The Broad Institute-MIT and Harvard

William (Bill) Mayo is the Chief Information Officer of the Broad Institute of MIT and Harvard in Cambridge Massachusetts. He also serves as the Chairman of the board of Ascentria Care Alliance, liaison to the College of Computer and Information Science at Northeastern University’s Venture Mentoring Network, and as an advisor to a private silicon valley technology company.

His career spans the consumer products, business services, life sciences, consulting, and social service sectors. He has led major projects, global teams, and business reviews in more than 25 countries, including product launches, M&A activity, and numerous projects.

In prior roles, Mr Mayo built a successful consulting business, worked closely on drug and product launches with Biogen, advised on technology strategy for a number of small biotechs, and he spent over 20 years with Gillette and Procter & Gamble. CIO magazine has recognized him as a Premier 100 IT Leader and he is a finalist for the 2018 CIO of the Year New England award.

Mr Mayor earned a B.S. in Computer Science and an MBA. from Northeastern University in Boston.

Stephen  Moran

Stephen Moran

Global Head of Strategy
Novartis

Stephen Moran is Global Head of Strategy for Novartis, a position he has held since January 1, 2017. Dr Moran joined Novartis in January 2015 as Strategic Assistant to the CEO. Prior to that, he was an Associate Principal at McKinsey & Company, serving as a leader in the healthcare practice. There his work focused on health system sustainability, research and development strategy and the economic analysis of clinical interventions across disease pathways. Dr Moran holds a Bachelor of Arts and a Master of Science in Natural Sciences from the University of Cambridge in the United Kingdom, and a doctorate in Biochemistry from the University of Oxford.

Alan Morrison

Alan Morrison

Vice President, Regulatory Affairs International, Global Regulatory Affairs & Clinical Safety
Merck Sharpe & Dohme

Alan Morrison serves as Vice President of Regulatory Affairs International at MSD. In this role, he leads the MSD international regulatory organisation across Europe, Middle East and Africa, Canada, Latin America and Asia Pacific, including responsibilities for China and Japan – one of the industry’s largest global geographic footprints. As well as being part of the global regulatory leadership team, Mr Morrison is also a member of the international cross-divisional leadership team defining the overall strategy and direction of the ex-US business and organisation.

Mr Morrison was previously Vice President, International Regulatory Affairs and Safety at Amgen. In that role, he was responsible for regulatory and safety teams across Europe, Latin America, Middle East and Africa, Canada, Asia Pacific, China and Japan. In addition, he led global labeling, regulatory writing, publishing and submissions capabilities, supporting all Amgen operating regions including United States.

Previously, Mr Morrison held leadership positions in global regulatory affairs at several multinational companies, including Celltech, Baxter, BMS and Johnson & Johnson. He is active in professional qualification and membership societies, including PhRMA, TOPRA and EFPIA. 

Mr Morrison participates in a number of trade association committees related to biotechnology / biopharmaceuticals. Notably, he is Chair of the EFPIA Regulatory Strategy Committee and Chair of the EFPIA Brexit Taskforce, and currently Chairman of the UK BioIndustry Association (BIA) Regulatory Affairs Committee. He holds a BSc in Biology and Physiology from the University of Stirling.

Nuala Murphy

Nuala Murphy

President
ICON Clinical Research Services

Nuala Murphy has been President of ICON Clinical Research Services since January 2014. Prior to this, she served as Executive Vice President of ICON’s global clinical and data operations. Dr Murphy has over 20 years’ experience within the pharmaceutical and CRO industry. She joined ICON in 2012 from Quintiles where she led a clinical and data management workforce. She also has over a decade of experience in therapeutics, having led the CNS and internal medicine project management divisions for Quintiles. She has also served in the field of late phase clinical research at Benefit International. During her tenure, she published extensively in eminent peer reviewed journals. Having graduated from Trinity College Dublin with a Bachelor of Science degree, Dr Murphy was awarded a PhD in Neurochemistry, from the Department of Cardiovascular Studies in Leeds and conducted post-doctoral research in the Department of Neuropharmacology at the Collège de France in Paris.

Andrew Obenshain

Andrew Obenshain

Senior Vice President and Head of Europe
Bluebird

Andrew Obenshain has served as head of Europe since 2016. He was most recently at Shire in Paris, France where he was the general manager of France and Benelux overseeing a portfolio including seven rare disease products. Prior to Shire, Mr Obenshain spent eight years at Genzyme and Sanofi holding roles of increasing responsibility in business development, marketing and global commercial operations. Mr Obenshain received his MBA from Northwestern University’s Kellogg School of Management, and his BA in Genetics, Cell and Developmental Biology from Dartmouth College.

Colin Orford

Colin Orford

Senor Vice President, Drug Development Services and Consulting
ICON

Colin Orford has 27 years of experience in the pharmaceutical sector gained at GSK (SmithKline Beecham), Novartis, Quintiles and Eisai which combines development strategy with operational execution.  He has 20 years of drug development experience having led multiple R&D project teams, and has worked across all stages of the development spectrum from Phase 0 through to Phase IIIb. He has lead therapy area strategy teams in Alzheimer’s, multiple sclerosis, MDD and auto-immune disorders.    Dr Orford has been responsible for transitioning multiple molecules, targeting MDD, Sleep disorders, Schizophrenia and Alzheimer’s Disease, from Phase 0, through proof of concept and, into late phase development.  He has also led a number of Phase III teams and has been involved in several NDA and MAA submissions. Colin currently leads ICON’s Drug Development and Consulting services.

Mene Pangalos

Mene Pangalos

Executive Vice-President, Innovative Medicines and Early Development Biotech Unit
AstraZeneca

Mene Pangalos is Executive Vice President of AstraZeneca’s Innovative Medicines and Early Development Biotech Unit and Global Business Development.  A member of the company’s Senior Executive Team, Dr Pangalos has overall responsibility for AstraZeneca’s research and early development activities spanning three continents and 2,500 people. 

Since joining AstraZeneca in 2010, Dr Pangalos has led a transformation of its R&D productivity resulting in a greater than four-fold increase in success rates compared to industry averages. In parallel, he has championed an open approach to working with academic and other external partners, changing the nature of academic-industry collaboration. 

One of AstraZeneca’s leading scientists, Dr Pangalos has published over 150 peer-reviewed articles in scientific journals and has served as editor of various books and journals.  He is a Visiting Professor of Neuroscience at King’s College London and the holder of an Honorary degree of Doctor of Science from Glasgow University.

Dr Pangalos makes a significant contribution to UK science. He is a Fellow of the Academy of Medical Sciences, the Royal Society of Biology and Clare Hall, University of Cambridge.  He sits on the Medical Research Council (MRC) Council, co-chairs the Life Sciences Council Expert Group on Innovation, Clinical Research and Data and is a member of the Life Sciences Industrial Strategy Implementation Board and National Genomics Board. He is also a Board member of the British Pharmaceutical Group and Cambridge University’s Judge Business School.

Umang Patel

Umang Patel

Clinical Director
Babylon

Umang Patel is Clinical Director at Babylon where his principal role is making sure that safe, effective and personalised healthcare is available to everyone, everywhere. He is also a practicing NHS Paediatrician at Frimley Park Hospital in Surrey. Dr Patel joined the NHS Leadership Academy as a Clinical Fellow in 2012. This set him on an alternative medical career path and he later became Head of Clinical Transformation at Aviva UK Health where he was responsible for a series of new initiatives to improve the model of healthcare delivery. Dr Patel also serves as a trustee of Attend, the UK’s national charity for volunteers.

John  Reynders

John Reynders

Vice President, R&D Strategy, Program Management & Data Sciences
Alexion Pharmaceuticals

John Reynders is Vice President, R&D Strategy, Program Management and Data Sciences at Alexion Pharmaceuticals, Inc. Dr. Reynders leads Alexion's data sciences and genomics capabilities with a focus on rare disease prevalence analytics, business development opportunity assessment, global patient footprint analytics, financial forecasting, and rare disease patient diagnostics. In this role, he also oversees R&D strategic planning and the Company’s R&D portfolio, as well as its integration across research, clinical, and commercial products, and business development assessment and integration. Prior to joining Alexion, Dr Reynders served as the CIO of Moderna Therapeutics, where he created a fully cloud-based biotech across all enterprise functions and developed informatics solutions to enable the design of messenger RNA therapeutics. Dr Reynders received his Bachelors, Summa Cum Laude, in Mathematics from Rensselaer Polytechnic Institute, his PhD. in Applied and Computational Mathematics from Princeton University, and an MBA from the Northwestern University Kellogg School of Management.

Bettina Ryll

Bettina Ryll

Founder
Patient Network Europe

After losing her husband to Melanoma, Bettina Ryll founded the Melanoma Patient Network Europe and developed a special interest in patient-centric clinical research, innovative trial designs and novel drug development concepts, such as MAPPS (medicines' adaptive pathways to patients). Lately, she has focuses on patient-relevant outcomes and sustainable healthcare models ensuring access to innovation for patients. Dr Ryll is involved in numerous initiatives promoting evidence-based advocacy. She is fascinated by the enormous potential and capacity of patient networks to both educate and support patients as well as to capture data at the primary data source, the patients themselves, to generate evidence at a granularity level non-accessible to outsiders.

Since 2015, De Ryll also chairs the ESMO Patient Advocates Working Group (ESMO-PAWG), the first time this position is held by a non-oncologist.

Dr Ryll holds a medical degree from the Free University of Berlin, Germany, and a PhD in Biomedical Sciences from University College London, UK. 

Mark Samuels

Mark Samuels

Chief Business & Strategy Officer
Medicines Discovery Catapult

Mark Samuels is Chief Business & Strategy Officer at the Medicines Discovery Catapult. In this role, he is responsible for business development, strategy, communications and research consortia. Previously, Mr Samuels founded the national Office for Clinical Research Infrastructure and was a founder member of the NIHR Strategy Board. With £1.1bn annual budget, the NIHR is responsible for NHS research across England. Mr Samuels also worked with Number 10 on David Cameron’s strategy for life sciences. At HIHR he established the organisation’s Translational Research Collaborations and chaired the creation of the UK’s Stem Cell Transplant Clinical Trials Partnership. Before NIHR, Mr Samuels was an executive at Roche Diagnostics. Representing the UK diagnostics industry, he co-chaired with Sir Andrew Dillon creation of the programme for NICE to evaluate diagnostics and medical devices. Educated at QMUL and Saïd Business School, Mr Samuels holds a Policy Fellowship at Cambridge University.

Kevin Shah

Kevin Shah

Head of Enterprise New Business
FUJIFILM Medical Systems Europe

Kevin Shah is Head of Enterprise New Business at Fujifilm Medical Systems Europe. Working with teams across Europe and Engaging with key customers, the company works to create long-term partnerships and help customers to overcome their daily challenges.

Fujifilm has an award winning portfolio of vendor neutral Healthcare IT solutions within its Synapse range and has recently been focusing on AI through its innovative REiLI platform and specifically enabling efficiency in Imaging departments with the use of AI enhancing the skills of Radiologists.

Mr Shah joined Fujifilm in 2015 and has previously worked at GE Healthcare, Ascom Healthcare and a variety of other IT companies. With a core focus on Imaging IT and the workflows and issues that surround modern complex Imaging Diagnostics departments.

Mr Shah has a keen interest in technology and in particular how it can effect change in the modern healthcare environment and enable better preventative healthcare and also more efficient clinical pathways and outcomes.

Keiron  Sparrowhawk

Keiron Sparrowhawk

CEO
My Cognition

Keiron Sparrowhawks’s 27-year pharmaceutical career in neuropsychiatric drug development and marketing concluded as the head of international pricing and reimbursement at GSK. He co-founded the pharma consultancy PriceSpective, in 2003, which had a highly successful exit in 2012, allowing Mr Sparrowhawk to focus on aligning neuroscience and technology to develop better neuropsychiatric assessments and interventions.

MyCognition originated from this inspiration and his experience of personal battles with mental illness. MyCognition is at the leading edge of cognitive health research and product development, with NHS approved apps to assess and promote cognition. Its mission is to help individuals with cognitive deficits, regardless of their age, gender or health status. The company operates internationally in the education, occupational- and community-health sectors, building on its R&D through commercial partnerships, with the potential to make a difference for millions of people.

Mr Sparrowhawk is the author of: Executive Function: Cognitive Fitness for Business, a source of wisdom in the mental health space, and an R&D specialist with a clear view of the evolving market landscape.  He lecturers at Cambridge university, is a speaker and investor.

Iain Stewart

Iain Stewart

President
National Research Council Canada
Simon Sturge

Simon Sturge

EVP, Head of Strategy and Operations
Merck

Simon Sturge is a recognised leader in the pharmaceutical industry with 32 years of experience, including 27 years in Biotech, of which 14 years as the CEO of several biotechnology companies. In his current role as EVP, Head of Strategy and Operations for Merck’s Biopharma business, Mr Sturge is leading Global Manufacturing and Supply, Quality, Allergopharma, Global Business Development and Alliance management, Marketing and Strategy Operations, Global Access and Pricing as well as Medical Devices and Services. Prior to his current role. Mr Sturge had oversight of all commercial regions for the company as Chief Operations Officer from 2015 until 2018. He joined Merck as Head of Biosimilars in 2013. Before Merck, Mr Sturge served as CEO of OctoPlus NV and Senior VP Biopharmaceuticals for Boehringer Ingelheim. Mr Sturge served as CEO of Vernalis from 2003-2008 where he applied his passion for business development to transform the company into a fully integrated specialty biopharmaceuticals business. Mr Sturge began his career on the ground as a sales representative. A gifted communicator, he ascended in roles of increasing seniority at Celltech – moving from Business Development to Marketing to Operations and finally to CEO in 1987.  As a testament to his leadership skills, Mr Sturge was awarded UK Mediscience CEO of the year in 2005. He holds a BSc Honors in Biology from the University of Sussex in the United Kingdom.

Ali Tehrani

Ali Tehrani

President & CEO
Zymeworks
Colin Terry

Colin Terry

R&D Strategy & Operations
Deloitte UK

Colin Terry is a Partner and leader in Deloitte’s UK / Swiss Life Science practice. He has been with Deloitte since 2011, working in the US firm until 2014 when he moved to the UK. Mr Terry’s client advisory work in the Life Sciences sector ranges from strategy into operations focused on the R&D function, including operating model development and implementation as well as post-merger integration (PMI). These engagements have been serving client Boards and their senior leadership teams in R&D, commercial and private equity. Mr Terry is the co-author of Deloitte’s annual R&D productivity and IRR analysis study which reviews productivity of the world’s largest pharmaceutical businesses. His recent engagements include developing a vision of the future R&D model including internal and external attributes; creating a digital R&D strategy and business cases of new technologies and pilot programs; design and implementation of a world first GXP validated Robotic Process Automation; and design of a new Pharma vaccine R&D model post integration. Mr Terry has
a BSc (Hons). in Microbiology from the University of London, Queen Mary & Westfield and a Marketing Diploma from the Chartered Institute of Marketing.

Rehan Verjee

Rehan Verjee

Executive Vice President, Chief Marketing and Strategy Officer
Merck Healthcare
Tony Wang

Tony Wang

COO
Color

Tony Wang is Chief Operating Officer of Color where he is responsible for the company’s commercial, operations and other G&A teams. Prior to Color, Mr Wang was Vice President of Global Revenue Partnerships and part of the executive team responsible for developing Twitter’s core commercial model and scaling global revenue teams. This followed a position as Vice President and Managing Director of Twitter Europe where he launched and managed revenue across European markets. Prior to Twitter, Mr Wang was Managing Counsel and member of the executive management team overseeing the Asia Pacific and Latin America markets for Google. Mr Wang also practiced law in the fields of M&A, capital markets and venture backed financings after graduating with a J.D. from Harvard Law School.

Yuan Xu

Yuan Xu

CEO
Legend Biotech

Yuan Xu joined Legend Biotech Corporation in 2018 and serves as CEO. Formerly, Dr Xu was Senior Vice President at Merck Research Laboratory, leading Biologics and Vaccines Discovery, Development and commercialisation activities. Prior to joining Merck, Dr Xu held executive positions and gained global operations experience with Gilead, Novartis, Amgen, Chiron, GSK and Genentech. Dr Xu has over 25 years of Biologics, Biosimilar, Vaccine and Cell Therapy discovery, development, commercialisation and life-cycle-management experience with contributions to successful BLA/MAA filings and commercial launches for 23 marketed products. Dr Xu completed postdoctoral training in Virology and Gene Therapy at the University of California, San Diego. She received her PhD in Biochemistry from University of Maryland at College Park and her B.S. in Biochemistry from Nanjing University in China.

Daphne Zohar

Daphne Zohar

Co-Founder and CEO
PureTech Health

Daphne Zohar is a Co­-Founder and the Chief Executive Officer of PureTech and a member of the Board. A successful entrepreneur, Ms Zohar created PureTech, assembling a leading team to help implement her vision for the Company, and attracting over $450 million to the Company and its operating companies. Ms Zohar has been recognized as a top leader and innovator in biotechnology by a number of sources, including BioWorld, MIT's Technology Review, the Boston Globe, and Scientific American. She sits on the boards of PureTech, the Sync Project, Akili Interactive Labs, Follica, Karuna and Tal. She also sits on the Technology Development Fund Advisory Board at Children's Hospital Boston and is an Editorial Advisor to Xconomy, a national news company.

fallback

Chaired by (7)

Sarah  Neville

Sarah Neville

Global Pharmaceuticals Editor
Financial Times

Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.

Clive Cookson

Clive Cookson

Science Editor
Financial Times

Clive Cookson is Science Editor at the Financial Times. He joined the newspaper in 1988 as Technology Editor and has also written about the chemical and pharmaceutical industries. Previously, he was the science and medical correspondent for BBC Radio. He also spent four years in Washington DC as American Editor of the Times Higher Education Supplement. He has won several science journalism awards and is an honorary member of the British Science Association and the American Academy of Arts and Sciences. Mr Cookson graduated from Oxford University with a first class honours degree in Chemistry.

David Crow

David Crow

Banking Editor
Financial Times

David Crow became Banking Editor of the Financial Times, based in London, in October 2018. He was previously the FT’s Senior US Business Correspondent, based in New York and covering primarily pharmaceuticals. Prior to that, he worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper. Mr Crow has an MA in English Literature from the University of Glasgow.

John Haughey

John Haughey

Industry Leader, Life Sciences & Health Care Practice North West Europe
Deloitte

John Haugheyis the industry leader for Deloitte’s Life Sciences & Healthcare practice in North West Europe. He has extensive experience in the life sciences industry as well as more broadly cross sector, having led multiple large-scale finance and back office transformations over the past 25 years.  He has operated across the full project lifecycle from feasibility through implementation.

Mr Haughey formerly led our CFO Advisory Practice which assists organisations in all aspects of finance transformation from strategy through implementation. His primary expertise relates to finance function improvement where he has led a number of major projects covering strategy, finance partnering, operational and financial improvement, ERP implementation, shared services, analytics, outsourcing and process reengineering.

Vanessa  Houlder

Vanessa Houlder

Lex Writer
Financial Times

Vanessa Houlder is a Lex Writer in London. She writes about European-listed companies, with a particular focus on the pharmaceutical sector. Prior to this, she was Tax Correspondent, Environment Correspondent, Technology Correspondent, Management Writer and Property Correspondent for the Financial Times. She has also written a column about UK smaller companies and reported on science and economics.

Andrew Jack

Andrew Jack

Global Education Editor
Financial Times

Andrew Jack has worked as a journalist for the Financial Times since 1990. He is currently the Global Education Editor, reporting and developing new projects including as editorial lead for free online FT access for schools. He previously ran the curated content team, picking the best news and analysis from the FT and the rest of the web, including FT Health. He was previously Deputy Editor of the Analysis section, Pharmaceuticals Correspondent, Moscow Bureau Chief, Paris Correspondent, Financial Correspondent, general reporter and corporate reporter. He is author of the books Inside Putin’s Russia and The French Exception, as well as numerous specialist reports, and has appeared on the BBC and other media outlets.

Greg Reh

Greg Reh

Global Life Sciences & Health Care Industry Leader
Deloitte

Greg Reh is a Global Life Sciences & Health Care Industry Leader and the Global Life Sciences Sector Leader for Deloitte Touche Tohmatsu Limited (Deloitte). He is also the life sciences sector leader for Deloitte in the United States. He has more than 25 years of experience in the life sciences, process manufacturing, consumer and government sectors. His consulting career has spanned such topics as technology strategy, integration solution development and implementation of emerging and disruptive technology. His clients have included multinational pharmaceutical, biotechnology and chemical manufacturing organizations where he successfully led consulting services in support of regulatory, clinical, commercialization and manufacturing operations.

Prior to his consulting career Greg held positions at a government research lab, where he led teams in the design and development of life support devices; and was a lecturer at the University of Pennsylvania.

fallback

Advisory Board (10)

Jessica Federer.

Jessica Federer.

Advisor
Hugo Health

Recognized as one of the top 100 global Chief Digital Officers (CDOs), a "Power-Lady" of the German economy, and a leading Health Tech Influencer, Jessica Federer is adept at translating digital developments into meaningful advancements for both business and society. After serving as the Chief Digital Officer for Bayer, Jessica is now an advisor for health and technology companies, and a Venture Affiliate Partner at Boston Millennia Partners. Prior to leading digital at Bayer, Federer held positions in Global Regulatory Affairs, Market Access, Communications and Public Affairs. She also served on the United Nations m-Powering Development Advisory Board for the Agency for Information and Communications Technology (ITU). Jessica began her public health career as an analyst at the Agency for Healthcare Research and Quality in the US Department of Health and Human Services. She earned a Bachelor of Science degree from the George Washington University, and a Master of Public Health from Yale.

Ulrich  Mühlner

Ulrich Mühlner

Founder and Managing Director
GrowthCube Partners

Ulrich Mühlner is a senior healthcare executive with 17 years of industry experience. In 2016, he started GrowthCube Partners and became an active startup investor and entrepreneur to enable life-changing healthcare innovations by joining forces with scientists, innovators, and entrepreneurs, and - together - translating groundbreaking ideas, discoveries, and inventions into services and products that make a real difference to people’s lives. Dr Mühlner is particularly passionate about radically transforming the pharma industry through Big Data, Artificial Intelligence, and Deep Learning. In addition, Dr Mühlner is the CEO, Chairman and Co-Founder of docdok.health Ltd, a recently founded company with the mission to transform the quality, delivery and experience of medical care for both doctors and patients through its innovative cloud-based connected personalised health communication platform. He also serves as the CEO of E-Medicus Ltd. and globally as board member and advisor to biopharma and digital health/health tech companies, as well as international organisations and  leading academic institutions. Previously, Dr Mühlner worked at Novartis and The Boston Consulting Group (BCG). At Novartis he served as Director and Head Global Corporate Strategy, Global Head Outcomes Technologies Incubator.In this role, he was responsible for the multi-billion dollar portfolio transformation strategy and spearheaded globally the digital health activities across Novartis leading to major digital health partnerships (Google/Verily, IBM, Proteus) with the aim to increase the value of the Novartis portfolio through ‘beyond-the-drug’ real-world outcomes solutions. In total, Dr Mühlner successfully executed deals with a volume of $350mn. Dr Mühlner studied Biochemistry in Hannover and Munich, and earned a PhD degree in Biochemistry and Molecular Biology based on his research on molecular mechanisms of cancer development at the Research Institute of Molecular Pathology (I.M.P.) in Vienna.

Lisa  Anson

Lisa Anson

CEO
Redx Pharma

Lisa Anson is Chief Executive Officer of Redx Pharma plc, appointed in June 2018. She held the post of President of AstraZeneca UK since 2012 and has significant leadership experience in pharmaceuticals. Over a 20 year career at AstraZeneca plc, Ms Anson held a number of senior management roles in both the US and the UK including Global Vice President, Oncology and as Vice President of emerging brands where she worked closely with the Research and Development teams. She joined Zeneca Pharmaceuticals (USA) in 1998 as a business development manager. Prior to this she worked for Salick Health Care (now Aptium), a California based cancer disease management company. Her first position upon graduating from university was with KPMG in London as a management consultant

Ms Anson is President of the Association of the British Pharmaceutical Industry (ABPI) a position from which she will step down in 2018. She has been a Board member of the ABPI since 2012 where she has chaired a number of UK industry committees and worked closely with Government.

Ms Anson holds an MBA (awarded with distinction) from INSEAD, France and a First Class honours degree in Natural Sciences from Cambridge University in the UK. 

Virginia Acha

Virginia Acha

Executive Director-Global Regulatory Policy, R&D Innovation Centre
MSD

Virginia (Ginny) Acha has worked in industry and academia throughout her career, combining interests in science policy research and innovation performance within and across organisations.  She recently joined MSD to lead regulatory policy efforts for innovation that will lead to better treatment for patients in Europe, the Middle East, Africa and Asia.  In particular, she is supporting work on real world evidence and integrated evidence generation. Before joining MSD, Dr Acha was the senior spokesman for the industry in the UK for research, medical and innovation policy.  She was responsible for ABPI’s work on Brexit for the life sciences sector.  Previously, Dr Acha worked for Amgen in global regulatory policy and for Pfizer working on policy development in science and innovation in healthcare. 

Christina Nesheva

Christina Nesheva

Operations Director, Hive Innovation Unit,
ViiV

Christina Nesheva drives corporate innovation from ideas to execution. She is the Operations director of the Innovation Unit of ViiV Healthcare, where she has been instrumental in the unit set-up and its development. Ms Nesheva’s main focus is on making corporate innovation work and deliver meaningful results. She has in-depth knowledge of tech and digital health trends and vast experience in applying lean startup and design thinking approaches to design new products and services and create more agile and innovative organisations.

Prior to joining ViiV Healthcare,Ms Nesheva held various leadership roles in general management, consulting, marketing and HR where she has created and scaled up new functions and units and delivered strategic change initiatives .Ms Nesheva has extensive experience in new product launches, has developed GSK’s global approach to launching new medicines and led the new product launch function for GSK Europe. Ms Nesheva holds an MBA from the London Business School.

Mike Standing

Mike Standing

EMEA Life Sciences and Healthcare Lead
Deloitte

Mike Standing is the Life Sciences and Healthcare industry leader for Deloitte for EMEA. Mr Standing has consulted to leading pharmaceutical and healthcare organisations in Europe, US and China for over 20 years, focusing on commercial strategy, operations and R&D productivity. In addition, he is currently leading major programmes to understand how real world evidence can transform health outcomes and productivity. He also advises governments on building healthcare clusters and is a member of the UK's Global Medical Excellence Cluster (GMEC) Advisory Board. Prior to joining Deloitte, Mr Standing was Co-Head of Life Sciences for the Monitor Group and Global Head of Capgemini's Life Sciences business. He is a graduate of Durham and Cambridge Universities and is based in London.

Richard  Mason

Richard Mason

Co-Founder
The Foundation Institute for 21st Century Medicine (C21Med)

Richard Mason, MD, is Co-Founder of The Foundation Institute for 21st Century Medicine (‘C21Med’), an initiative of venture capital firm Medicxi

Dr. Mason served as Head of Johnson & Johnson’s London Innovation Centre from October 2015 to April 2018, where he was responsible for Johnson & Johnson Innovation within the EMEA region. In this role, Dr. Mason led a team of transaction and scientific innovation experts to identify and develop a diverse portfolio of early-stage partnerships and investments across all three sectors of J&J.
 
Prior to joining J&J, Dr Mason was CEO of a venture-backed biotechnology startup, XO1 Ltd. until the company was acquired by Janssen Pharmaceuticals (a subsidiary of J&J) in March 2015. Prior to that, he was Head of Strategy and Business Development and member of Executive Leadership Team at specialty pharmaceutical and medical device company BTG Plc (LON: BTG), where he led its transformation into a leading interventional medicine company through multiple acquisitions including Ekos Corporation, Biocompatibles Plc, and MDS Nordion’s Therasphere business. Dr.Mason also served as an Executive-in-Residence for Advent Venture Partners where he served as a turnaround CEO for several portfolio companies. Prior to that he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT) and member of the CAT Executive Leadership Team.
 
Dr. Mason trained in Medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree in immunology from University College, London and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management.

Francesco  De Rubertis

Francesco De Rubertis

Founder and CEO
Medicxi

Francesco De Rubertis is Partner and Co-Founder of Medicxi. Prior to this, he was with Index Ventures for 18 years, having joined the firm in 1997 to launch its life sciences practice. While at Index life sciences, he spearheaded the creation and adoption of an asset-centric investment strategy and led the growth of the firm. At Medicxi he also oversees the firm’s operations. Among Dr De Rubertis’s investments are CellZome (acquired by GlaxoSmithKline), Egalet (NASDAQ: EGLT), GenMab (NASDAQ Copenhagen: GEN), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Minerva Neurosciences (NASDAQ: NERV), Molecular Partners (Swiss: MOLN.SW), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix, NASDAQ: AFFX), Profibrix (acquired by The Medicines Company), and Versartis (NASDAQ: VSAR). Dr De Rubertis received a BA in Genetics and Microbiology from the University of Pavia and a PhD in Molecular Biology from the University of Geneva, and was then a postdoctoral scientist at the Whitehead Institute at MIT. He is a Chartered Financial Analyst and serves on the main board of the University of Geneva. Dr De Rubertis was named by BioWorld as one of 28 “movers and shakers” predicted to shape the biotechnology industry over the next two decades.

Colin Orford

Colin Orford

Senor Vice President, Drug Development Services and Consulting
ICON

Colin Orford has 27 years of experience in the pharmaceutical sector gained at GSK (SmithKline Beecham), Novartis, Quintiles and Eisai which combines development strategy with operational execution.  He has 20 years of drug development experience having led multiple R&D project teams, and has worked across all stages of the development spectrum from Phase 0 through to Phase IIIb. He has lead therapy area strategy teams in Alzheimer’s, multiple sclerosis, MDD and auto-immune disorders.    Dr Orford has been responsible for transitioning multiple molecules, targeting MDD, Sleep disorders, Schizophrenia and Alzheimer’s Disease, from Phase 0, through proof of concept and, into late phase development.  He has also led a number of Phase III teams and has been involved in several NDA and MAA submissions. Colin currently leads ICON’s Drug Development and Consulting services.

Tim de Gavre

Tim de Gavre

Country Head UK
Sandoz
fallback

Agenda - 5th Nov

  • 12:00pm
    Registration & networking lunch
  • 1:00pm
    Opening Remarks from the Chair

    Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 1:05pm
    CEO Keynote Address/Interview

    Christophe Weber, President  & CEO, Takeda in conversation with Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 1:25pm
    Panel: Big Bang? Industrial Strategy - Creating a Successful Life Sciences Economy

    The UK has recently announced its sector deal for life sciences as part of its Industrial Strategy. Other countries around the world are also making efforts to build their life sciences sectors in recognition of the industry’s hoped for contribution to economic growth.

    • How effective will the UK’s life sciences strategy be in achieving its stated objectives? What difference will it make? Will it provide a ‘big bang’ for life sciences? Will it enable patients to achieve ‘the best standards of care’ and improve access?
    • Are healthcare systems ready and able to adopt and support the innovation which will emerge from these industrial strategy endeavours? Is the necessary alignment of payment, regulatory and development models in place to ensure success?
    • What does it take to create a truly competitive life science industry? How do you ‘go beyond the network’, for instance, to enable the innovation at the interface between industry academia and healthcare systems that creates new sources of data and the development of new drugs?
    • What is the role of clusters/ ecosystems, and how sustainable are all the new clusters/superclusters as growing numbers of countries competing in this space?
    • How important is life science to the economy, and it is money invested well?

     

    Professor Sir John Bell, Regius Professor of Medicine, Oxford University

    Yves Dubaquie, Head of Corporate Business Development, Life Sciences, Merck

    Jane GriffithsGlobal Head, Actelion

    Bruno Holthof, CEO, NHS Oxford University Hospitals

    Bernard Massie, Director General, Human Health Therapeutics Research Centre, National Research Council Canada

    Moderator: John Haughey, Industry Leader, Life Sciences & Health Care Practice North West Europe, Deloitte

  • 2:25pm
    Keynote Interview:

    Mene Pangalos, Executive Vice President, Innovative  Medicines and Early Development Biotech Unit and Global Business Development, AstraZeneca in conversation with Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 2:45pm
    Networking Coffee Break
  • 3:10pm
    Keynote: The Future for Generics and Biosimilars

    Richard Francis, CEO, Sandoz

  • 3:30pm
    Keynote Interview

    Hal Barron, Chief Scientific Officer and President, R&D, GlaxoSmithKline in conversation with Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 3:45pm
    China - A Disruptive Force in Life Sciences: Leader or Follower?

    China is stepping up its investment in life sciences, and is aiming to take a lead in key emerging areas to include genomics, gene editing and gene therapies. It is also now the second largest pharmaceutical in the world and is facing an epidemic of chronic and age related diseases. Recent moves by the industry regulator are paving the way for faster drug approvals and greater access for patients to advanced therapies. Meanwhile, China is embracing digital at a pace which eclipses the efforts in most other countries, and lacking the burden of legacy primary health care systems, is creating innovate new treatment and service models.

    • How is healthcare reform and the regulatory environment for life sciences in China evolving and what does it mean for pharma?
    • How is digital health evolving in China? What innovative approaches and strategies is China adopting to deal with ageing and management of chronic diseases? What are the implications of China’s approach to data as a public asset?
    • Will China be a leader or follower in drug development? What is the true level of innovation and ambition in China-the vision of China innovation 2020/2025?
    • What R&D strategies are Chinese life sciences company’s adopting, and what are the barriers to Chinese companies becoming fully fledged drug innovators? How might the emergence of Chinese innovation redefine the pathways for discovery and development of new drugs? What new innovations and approaches could we see emerging?
    • Will Chinese life sciences companies steal a lead by virtue of prowess in AI, computing, genomics and more lapse regulations with regard to advanced gene-based medicine?

    Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, AstraZeneca

    Christian Hogg, CEO, Chi-Med

    Yuan Xu, CEO, Legend Biotech

    Alan Morrison, Vice President, Regulatory Affairs International, Merck Sharpe & Dohme

    Umang Patel, Clinical Director, Babylon

    Moderator: Andrew JackGlobal Education Editor, Financial Times

  • 4:35pm
    Keynote

    Nuala Murphy,  President, Clinical Services, ICON in conversation with Andrew Jack, Global Education Editor, Financial Times

  • 4:55pm
    Investor Panel

    In this session our panel of leading investors – to include leading fund managers, corporate venture and charity investors - will share their views on the outlook for the industry and challenges ahead. The session will include views on the current round of deal making /M&A and consolidation and the implications for the industry. Will investors provide patient long-term capital to support the industry’s on-going transformation, including digital initiatives without proven IP and a framework for the valuation and monetisation of data, and potentially lower initial margins? Where do investors see opportunities emerging?

    Deborah Harland, Partner, SR One

    Sohini Chowdhury, Deputy CEO, Michael J. Fox Foundation 

    Paul Major, Portfolio Manager, BB Healthcare Trust 

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 5:25pm
    Drinks Reception
  • 6:30pm
    Close of Day One

Agenda - 6th Nov

  • 9:00am
    Opening Remarks from the Chair

    Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 9:05am
    Panel: Big Data, Big Deal?

    What will it mean for the industry as payers continue to make advances in their ability to have continuous, real-time data enabling them not only to monitor and compare effectiveness of drugs, but to continuously assess the health of patients? How are payers strategies evolving in this space? In theory, this will lead to better patient care and better clinical trials, but there are many challenges remaining before the ‘data utopia’ becomes a reality, to include the lack of agreement on differing definitions of what constitutes value. How far are we from achieving the data utopia which underpins the many industry efforts to achieve greater productivity and patient focus with the help of technology? Does date have real value, and how do you get that value? Has data become too much, too complex and beyond the ability of life science and regulators to manage it? How much evidence is enough? Or too much? Where do we go from here? Enormous advances in gathering date and evidence, have been made but implementation has been challenging: Is the next stage of the digital health revolution a move to simplicity (e.g. the Uber health application)?

    William Mayo, Chief Information Officer, The Broad Institute-MIT and Harvard

    Peter Donnelly, Founder and CEO, Genomics plc, and Professor of Statistical Science in the Wellcome Centre for Human Genetics, University of Oxford

    Pamela Cyrus, Vice President and Glo0bal Head of Medical Governance, Bayer Pharmaceuticals

    Rajni Aneja, Advisory board member MIT Connection Science and Fellow @ connection science 

    Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 9:55am
    Panel: Innovate Like a Start-Up: A New Future for R&D?

    In this session, our panel of leading Heads of R&D will share their views on the challenges facing R&D, and the strategies and approaches to reinvigorate drug development and research. Issues to be addressed could include:

    • New R&D models-prospects and challenges of public-private partnerships. Will we see more collaborations between government and industry to resolve the big research challenges which are beyond the capacity for big pharma to handle alone (e.g Alzheimer’s)?
    • How are R&D departments delivering on their ambition to do research more like entrepreneurial biotechs?
    • Virtual clinical trials-what do we need to do to make this a reality? Can clinical trials become treatment options?
    • The digital prescription for R&D – is big data slowing down drug development?
    • Digital therapeutics-what’s the verdict?
    • Is there a case for optimism in R&D?

    Colin Orford, Senior Vice President, Drug Development Services and  Consulting, ICON

    Mark Samuels, Chief Business & Strategy Officer, Medicines Discovery Catapult

    Colin TerryPartner, R&D Strategy & Operations, Deloitte

    Daphne Zohar, Founder and Chief Executive Officer, PureTech Health

    Moderator: Clive Cookson, Science Editor, Financial Times

  • 10:35am
    Networking Coffee Break
  • 10:55am
    Panel: Partnerships and Collaborations: What Works and Doesn't Work?

    The aim of this session is to provide visibility regarding what’s working and not working in the multiple types of partnering and collaborations being undertaken and explored by life sciences companies-from JV, to licensing to consortia and tie-ups increasingly with non-traditional industry players.

    • What’s working and not working? What have been the successes and challenges?
    • What are the trends in collaboration and partnering?
    • What novel types of collaborations might we see emerging?

    Matt Cooper, Business Development and Marketing Director, National  Institute for Health Research (NIHR)

    Mark Douglas, Vice President, Strategic Business Development, FUJIFILM Diosynth Biotechnologies

    Thomas Eichholtz, Executive Director of External R&D, Mundipharma Research

    Moderator: Vanessa Houlder, Lex Writer, Financial Times

  • 11:35am
    Panel: Patient-Centred Care and Patient - Centred Outcomes: Hope or Hype?

    Life science companies are working to place ‘serving the patient’ at the centre of their mission. The capture of patient focused data is becoming an essential part of drug approval and the reimbursement process and a focus on patient centricity helps build patient trust, can improve outcomes and adherence and help gain better acceptance by payers, providers, regulators and patients.

    • What are the strategies to support patient centricity on a full life-cycle basis? How is a focus on the patient impacting decision making? What does an all embracing, patient-centric life science company of the future look like? Are patient-centric approaches delivering on ROI?
    • How do you build a patient-centric corporate culture?
    • How are regulation and payer requirements regarding patient centricity and outcomes evolving?
    • Case study of a patient journey in one disease area: what were the experiences and learnings? How do patients define value and how do you measure it?

    Julie Gerberding,  Executive Vice President, Communications, Global Policy and Population Health & Chief Patient Officer, MSD

    Mike Gladstone, Global President,  Internal Medicine, Pfizer 

    Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency (EMA)

    Joanne Waldstreicher, Chief Medical Officer, Johnson & Johnson 

    Christopher Boerner, Executive Vice President and Chief Commercial Officer, Bristol-Myers Squibb

    Moderator: Greg Reh, Global Life Sciences and Healthcare Industry Leader, Deloitte

  • 12:25pm
    Keynote Interview : Medicinal Cannabis: Perspectives on a Growing Market, Evolving Regulations and a Nascent Supply Chain

    Andrew Badrot, CEO, C2 PHARMA  in conversation with Clive Cookson, Science Editor, Financial Times

  • 12:45pm
    Lunch
  • 1:50pm
    New Industry Paradigms: Prevention - What is the Role for Pharma in Population Health Management?

    A focus on prevention and its potential for cost savings will become increasingly important if healthcare systems are to be able to afford the highly innovative, high-cost drugs which are coming our way. However, interventions focused on prevention are difficult to test and validate, and the economics are also fundamentally challenging. How can pharma play a role and excel in this space? Can the industry make money from prevention? What does it take to succeed in this space (e.g owning a consumer business)?

    Chris Edson, CEO, OurPath

    Niels Lund, Vice President, Health Advocacy, Novo Nordisk

    Keiron Sparrowhawk, Chief Scientific Officer and Founder, MyCognition

    Jay Hamilton, Associate Director, Health Innovative Manchester

    Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 2:30pm
    Panel: From Treatment to Cure- How will gene and cell-based therapies transform medicine and healthcare?

    Long considered the holy grail of medicine, the era of genetic medicine is dawning at last. The recent FDA approval of a gene therapy marks the advent of a new era of cell and gene- based therapies that try to hack the body’s biology to tackle disease and hold out the promise of a paradigm shift from treatment to cure. Will gene therapies become the mainstay in treating and possibly curing our most devastating and intractable diseases?

    • How can pharma work with effectively with healthcare providers and patients to bring the benefits to patients?
    • Given the high price tag, what will be the impact on healthcare systems and how can they be paid for?
    • What are the viable alternative pricing and financing models to ensure the full potential of these new treatments are realized, and their affordability and access is assured?
    • How do you value and put a price tag on potential cures?
    • What are the viable alternative pricing and financing models to ensure the full potential of these new treatments are realized and their affordability and access is assured?

    Andrew Obenshain ,Senior Vice President and Head of Europe, Bluebird Bio

    Katrine Bosley, CEO, Editas Medicine

    Stephen Moran, Global Head of Strategy, Novartis

    Chris Hollowood, Chief Investment Officer, Syncona

    Bettina Ryll, Founder, Melanoma Patient Network Europe

    Moderator: Greg Reh, Global Life Sciences and Healthcare Industry Leader, Deloitte

  • 3:20pm
    Keynote Interview: Disciplined Innovation

    Ken Gabriel, President and CEO, Draper in discussion with Vanessa Houlder, Lex Writer, Financial Times

  • 3:40pm
    Networking Coffee Break
  • 4:00pm
    Panel: Envisioning the Future of Diagnostics

    Some 70% of medical decisions, it is claimed are driven by diagnostics. As we enter the era of precision medicine, tailored therapeutics and AI, and as ever more rare diseases are investigated, diagnostics will continue to grow and the definition of what constitutes diagnostics will evolve.

    • A vision for the future of diagnostics
    • How will AI transform diagnostics?
    • The role of digital diagnostics-how robust are they? The challenges of regulating medical algorithms
    • Regulation and reimbursement challenges
    • Beyond oncology: prospects for expanding RX/DX/companion diagnostic to chronic disease and other disease states
    • Opportunities and challenges of early stage diagnostics
    • Next Frontiers in diagnostics: Immune system mapping and diagnostics: facial recognition diagnostics
    • The pitfalls of genetic testing-will we overwhelm the health system with the worried well?

    Billy Boyle, Founder and CEO, Owlstone Medical 

    Philip Maurer, Pharmaceutical and Health Care Engineering Lead, Google Cloud, UK

    John ReyndersVice President, R&D Strategy, Program Management & Data Sciences, Alexion Pharmaceuticals

    Kevin Shah, Head of Enterprise New Business, FUJIFILM Medical Systems Europe

    Tony Wang, Chief Operating Officer, Color Genomics

    Moderator: Greg Reh, Global Life Sciences and Healthcare Industry Leader, Deloitte

  • 4:45pm
    Win Big, Lose Big? An Industry Call to Action

    Beyond R&D, how will tech and data disruption potentially transform other aspects of the business, to include commercial and supply chain? Will digital spell the end of the sales force and marketing as we know it? Will the industry become increasingly commoditised as these disruptions gradually chip away at all aspects of the business? Is the era of complacency regarding the disruptions set to reshape the industry now over? Will completely new business, skills and leadership models be needed? What is the key to surviving and thriving in this new era?

    Simon Sturge, Executive Vice President, Head of Strategy and Operations, Merck

    Lisa Anson, CEO, Redx Pharma 

    Leslie Krumholz,CEO, Hugo Health

    Richard Mason, Co-Founder, The Foundation Institute for 21st Century Medicine

    Moderator: Sarah Neville, Global Pharmaceutical Editor, Financial Times

  • 5:25pm
    Closing Remarks from the Chair

    Sarah Neville, Global Pharmaceutical Editor, Financial Times

  • 5:30pm
    Networking Drinks Reception

Why Attend?

  • Debate the role of super clusters and industrial strategy in creating a ‘big bang’ in life sciences
  • Discover how China’s novel approaches to R&D, data and digital health are creating innovate treatment and service models
  • Discuss what it takes for pharma to win in population health management and the business of prevention
  • Learn how innovative gene-based therapies are transforming the industry paradigm from treatment to cure and the pricing strategies to manage it.
  • Envision the future of diagnostics and personalised medicine
  • Hear from leading fund managers, corporate venturers, and other investors on where they are placing bets in pharma
  • Be part of the discussion on value and evidence and the challenge of managing the increasing volume and complexity of big data
fallback

Who Attends?

FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years.

The FT Global Pharmaceutical and Biotechnology Conference will be attended by:

  • Pharmaceutical companies
  • Biotechnology companies
  • Diagnostic and medical devices
  • CROs
  • Healthcare providers and insurers
  • Government healthcare departments, HTA’s and drug regulators
  • Digital health companies
  • Genomics and personalised medicine experts
  • IT, big data and analytics providers
  • Health economists
  • Healthcare investment bankers, private equity and venture capitalists
  • Healthcare lawyers and management consultants
  • Patient representatives and NGOs
fallback

Fees

Ticket

Fee

Super Early Bird (ends 22 March)

£1699.00

Early Bird (ends 28 May)

£1799.00

Standard Summit Ticket

£1899.00

fallback

Sponsorship Opportunities

  • Gain access to 350 Senior Executives from the Pharmaceutical and Biotechnology industry, who will be attending the event;
  • Brand alignment with the FT and its unrivalled credibility;
  • Demonstrate thought leadership around the current critical issues affecting the Pharmaceutical and Biotechnology industry;
  • Benefit from sustained international visibility through our advertising and marketing campaigns

Joe Hames

Commercial Manager, Global Industries

T: +44 (0)207 873 4551

M: +44 (0)791 329 2038

E: joe.hames@ft.com

fallback

Presented by (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.

With the support of (1)

About Life Sciences and Health Care at Deloitte

Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

Lead Sponsor (5)

ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.

ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.

With headquarters in Dublin, Ireland, ICON currently, operates from 93 locations in 37 countries and has approximately 13,650 employees. For further information please visit www.iconplc.com  Follow @iconplc on Twitter.

C² PHARMA (www.c2pharma.com) is a Luxembourg-based pharmaceutical group established in 2014. It manufactures and distributes active pharmaceutical ingredients (APls) and mcomplex chemical compounds obtained from natural and synthetic origins.

The current API product portfolio includes atropine, digoxin, homatropine, pilocarpine, and N-butylbromide scopolamine/hyoscine (SNBB). A recent R&D pipeline extension was announced into 10 new APIs and three botanical extracts in parallel to a major initiative for the development of Cannabis-based APIs and botanical extracts. C² PHARMA reaches more than 100 pharmaceutical companies directly across the United States, Western and Eastern Europe, South America, Asia, Middle-East and Africa.

C² PHARMA is a key sponsor of the “Partnerships for a Better World” program that ensures sustainable, traceable and fair-trade harvesting and sourcing of raw materials for the manufacturing of APIs, such as pilocarpine. The program sustains more than 1,000 families and contributes to the preservation of Brazilian biodiversity.

C² PHARMA also offers customized cold-chain logistics solutions through its specialized affiliate Logistics4Pharma (logistics4pharma.com), as well as R&D-scale contract synthesis services, analytical services, phytochemical profiling and impurities manufacturing through its affiliate ASM Research Chemicals (www.asm-research-chemicals.de).

From being the first engineers to guide and navigate humans to the moon and back to creating today’s most advanced systems that drive down the cost and increase the quality of the latest precision medicine breakthroughs, Draper engineers possibilities to overcome the world’s most pressing challenges.

As an independent, nonprofit engineering company, Draper uses its multidisciplinary expertise in areas including autonomous systems and image & big data analytics to materials and microsystems, to design, develop and deploy new technological solutions. Delivering to clients in government and industry capabilities that fundamentally challenge and change world views of the seemingly impossible.

FUJIFILM Holdings Corporation, headquartered in Tokyo, Japan, brings innovative solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies derived from photographic film. Fujifilm’s proprietary core technologies contribute to the fields of healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on Fujifilm’s extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies.

By leveraging these core technologies and proactively pursuing advanced R&D, Fujifilm is entering a new era, striving to push the boundaries of innovation to help make the world a better and healthier place. Through capital investment, R&D investment and strategic M&A, Fujifilm is exploring new possibilities in areas including biotechnology, pharmaceuticals and regenerative medicine.

Fujifilm’s first steps into healthcare came with the development of X-ray film in 1936, and later advances delivered a long line of breakthrough diagnostic technologies including digital radiography, endoscopy and healthcare IT. In 2006, Fujifilm entered the preventive medicine field, offering functional cosmetics and supplements. In 2008, Fujifilm welcomed drug company Toyama Chemical into the Group, entering the pharmaceutical industry. Today, Fujifilm’s healthcare capabilities now span from the large-scale manufacturing of induced pluripotent stem cells for use in drug discovery and regenerative medicine to becoming the CDMO partner of choice for biologics manufacturing and vaccine development.

In 2017, FUJIFILM Corporation was named a Clarivate Top 100 Global Innovator for the sixth year in a row, in recognition of its achievements as one of the world's most innovative companies.

Associate Sponsor (2)

Google Cloud is widely recognized as a global leader in delivering a secure, open, intelligent and transformative enterprise cloud platform. Our technology is built on Google’s private network and is the product of nearly 20 years of innovation in security, network architecture, collaboration, artificial intelligence and open source software. We offer a simply engineered set of tools and unparalleled technology across Google Cloud Platform and G Suite that help bring people, insights and ideas together. Customers across more than 150 countries trust Google Cloud to modernize their computing environment for today’s digital world.

The Mundipharma global network of privately-owned independent associated companies (‘Mundipharma’) is equivalent to a mid-sized global pharmaceutical company. Central to our success is our focus on partnerships. We partner to accelerate the delivery of medicines to patients with unmet medical needs. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries, employing over 8,600 people.

Supporting Organisations (3)

The European Medical Journal is an independent, open-access eJournal dedicated to delivering first-class insights into ground-breaking changes, and advancements in medicine. Spanning sixteen therapeutic areas, including Innovations, Cardiology, Oncology, and more, each journal provides the reader with the latest medical congress highlights, abstract reviews, and peer-reviewed articles to name but a few of its wide content selection. Flagship EMJ journals are also published quarterly, bringing an assortment of research papers from a variety of topics.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 40 leading pharmaceutical companies, EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy. Our vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and better outcomes for patients. 

PHARMAnetwork magazine covers, every aspect of pharmaceutical value chain, the change and developments in the intersection between pharmaceutical industry and outsourcing industry.

Venue

Royal Lancaster
Lancaster Terrace
London W2 2TY

United Kingdom

Tel: +44 207 551 6000

fallback

Accommodation

To book accommodation at special rates please click this link.

fallback

Contact us

Alexsandra Silva
Media Partner and Press Enquiries
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times
Joe Hames
Sponsorship Opportunities
Financial Times
FT Live Delegate Services - EMEA
Delegate Booking and Registration Enquiries
Financial Times